Daily Ards Research Analysis
Analyzed 8 papers and selected 3 impactful papers.
Summary
Methodological innovation in 3D spatial transcriptomics reveals interferon-linked micro-architectural changes in COVID-19 ARDS lungs. A scoping review quantifies the high burden and mortality impact of AKI in ARDS, highlighting lung–kidney crosstalk. A single-center cohort proposes a PRESERVE-CO2 score to aid ECCO2R patient selection in hypercapnic respiratory failure.
Research Themes
- 3D spatial transcriptomics and ARDS lung micro-architecture
- Lung–kidney crosstalk: AKI burden and outcomes in ARDS
- Prognostication and patient selection for ECCO2R in hypercapnic failure
Selected Articles
1. SM3DD with segmented PCA: a comprehensive method for interpreting 3D spatial transcriptomics.
This study introduces SM3DD, a segmentation-free 3D spatial metric that quantifies nearest-neighbor transcript distances and reveals functional organization in human lung tissue. Applied to COVID-19 ARDS lungs versus controls, SM3DD and segmented PCA highlighted interferon-related signaling (e.g., FKBP11 proximity to MZT2A) and recovered pathway signatures, including 'SARS-CoV-2 infection', despite no viral transcripts on the panel.
Impact: Provides a robust, annotation-free framework for interpreting 3D spatial transcriptomics in ARDS lungs, enabling discovery of immune signaling topology directly in tissue. This methodological advance can generalize to other diseases and platforms.
Clinical Implications: While not directly practice-changing, the method supports discovery of spatial biomarkers and pathways in ARDS, informing target identification, sampling strategies, and potential response biomarkers for future trials.
Key Findings
- Introduced SM3DD, a segmentation/annotation-free 3D nearest-transcript distance metric for spatial RNA data.
- In COVID-19 ARDS lungs versus controls, decreased distance between FKBP11 and MZT2A suggested interferon signaling involvement.
- Segmented PCA on SM3DD recovered multiple pathways, including 'SARS-CoV-2 infection', despite absence of viral transcripts on the panel.
Methodological Strengths
- Cell segmentation–free analysis reduces annotation bias and preserves spatial resolution.
- Unsupervised hierarchical clustering and segmented PCA provided functional organization and pathway-level insights.
Limitations
- Modest sample size from post-mortem lung tissues and single platform.
- Lack of external validation and causal inference; observational cross-sectional design.
Future Directions: Validate SM3DD across platforms and ARDS etiologies, integrate with proteomics/imaging, and test predictive value for clinical outcomes and therapy response.
We developed Standardised Minimum 3D Distance (SM3DD), an entirely cell segmentation/annotation-free approach to the analysis of spatial RNA datasets, using it to compare lung tissue from 16 clinically normal individuals to that of 18 SARS-CoV-2 patients who died from acute respiratory distress syndrome. RNA spatial coordinates were determined using the CosMx™ Spatial Molecular Imager (Bruker Spatial Biology, US). For each individual transcript location, we calculated the three-dimensional distances to the nearest transcript of each transcript type, standardising the distances to each transcript type. Mean SM3DDs were compared between normal and SARS-CoV-2 patients. Notably, hierarchical clustering of the directional log10(P) values organized genes by functionality, making it easier to interpret biological contexts, and for FKBP11, where a decrease in distance to MZT2A was the most significant difference, suggesting a role in interferon signalling. Using a segmented principal components analysis of the entire SM3DD dataset, we identified multiple pathways, including 'SARS-CoV-2 infection', even though the assay did not include any SARS-CoV-2 transcripts.
2. Acute respiratory distress syndrome and acute kidney injury in critically ill patients: A scoping review on this lung-kidney crosstalk.
Across 28 observational studies, nearly half of ARDS patients developed AKI (pooled 46.8%), and ARDS-AKI was consistently associated with higher hospital mortality than ARDS alone. Evidence heterogeneity limited mechanistic conclusions, but two studies identified ARDS as an independent AKI risk factor; reporting on AKI recovery was scarce.
Impact: Defines the magnitude and outcome impact of AKI in ARDS, clarifying the clinical burden and evidentiary gaps in lung–kidney crosstalk. Provides a foundation for targeted prevention and kidney-protective strategies in ARDS care.
Clinical Implications: Supports early kidney risk assessment and monitoring in ARDS, careful application of nephrotoxic exposures, and consideration of kidney-protective bundles; highlights need for standardized reporting of AKI recovery and KRT use.
Key Findings
- Pooled AKI incidence in ARDS was 46.8% (95% CI: 40.8–52.8) across included studies.
- ARDS-AKI carried higher hospital mortality than ARDS alone in 17 studies.
- Two studies identified ARDS as an independent risk factor for AKI; AKI recovery was infrequently reported.
Methodological Strengths
- Conducted per JBI and PRISMA-ScR with multi-database search (MEDLINE, Embase, LILACS).
- Predominant use of KDIGO criteria enhanced comparability of AKI definitions.
Limitations
- Only observational studies with high heterogeneity; limited ability to infer mechanisms.
- No quantitative meta-analysis of effect sizes; sparse data on AKI recovery and timing.
Future Directions: Prospective multicenter studies to delineate lung–kidney mechanisms in ARDS, trials of kidney-protective strategies, and standardized outcome reporting including AKI recovery and KRT metrics.
INTRODUCTION: The incidence of acute kidney injury (AKI) in patients with acute respiratory distress syndrome (ARDS) is high; nonetheless, the lung-kidney crosstalk remains unclear. OBJECTIVE: Describe the association between ARDS and AKI in critically ill patients. METHODS: This scoping review was conducted according to the JBI and PRISM-ScR and included studies that investigated critically ill patients with ARDS (Participants), described AKI-related outcomes (Concept), and were conducted in hospitals (Context). MEDLINE, Embase, and LILACS databases were searched for articles published up to January 2024. Only observational studies were considered. Data on the diagnosis of ARDS-AKI and other kidney-related outcomes were extracted. RESULTS: A total of 2943 studies were screened, of which 28 were included in this review. Most studies were prospective and the majority originated from Europe. AKI was diagnosed using the KDIGO criteria in most studies and the pooled overall rate of AKI development across the studies was 46.8% (95% CI: 40.8-52.8). Two reports identified ARDS as an independent risk factor for AKI. Kidney replacement therapy was described in 17 studies. AKI recovery was described in only three studies. Seventeen studies evaluated hospital mortality, specifically in patients with ARDS-AKI, and found a greater mortality risk as compared to only ARDS. CONCLUSIONS: This scoping review emphasizes the variability of the evidence, which hinders definitive conclusions about the association between ARDS and AKI, despite their common occurrence in critically ill patients. Therefore, a significant gap remains in our understanding of this lung-kidney interaction.
3. Prediction of long-term mortality in acute hypercapnic respiratory failure with use of low-flow veno-venous extracorporeal CO2 removal (ECCO2R): A retrospective single-center study.
In 70 patients undergoing low-flow vv-ECCO2R for hypercapnic respiratory failure, a modified PRESERVE-CO2 score discriminated 180-day mortality (AUC 0.78) with a suggested cutoff of 7, whereas a modified RESP-CO2 score did not. Mortality was highest in pulmonary fibrosis and bronchiolitis obliterans syndrome, and with >6 days of mechanical ventilation before ECCO2R.
Impact: Addresses a key barrier to ECCO2R trial efficacy by proposing a practical prognostic tool for patient selection in hypercapnic failure, including ARDS.
Clinical Implications: Supports triage for ECCO2R using PRESERVE-CO2 (avoid treatment in those with scores ≥7 and prolonged pre-ECCO2R ventilation), potentially improving outcomes and resource allocation pending external validation.
Key Findings
- 180-day mortality was 45.7% overall; highest in pulmonary fibrosis and bronchiolitis obliterans syndrome, and when ventilation exceeded 6 days pre-ECCO2R.
- Modified PRESERVE-CO2 score separated survivors vs non-survivors (4.3 ± 2.2 vs 6.9 ± 2.6; p < 0.01) with ROC AUC 0.78 and suggested cutoff of 7.
- Modified RESP-CO2 score showed no significant discrimination in this cohort.
Methodological Strengths
- Prospective capture of clinical and respiratory variables with predefined ECCO2R initiation thresholds.
- Heterogeneous etiologies (including ARDS, COPD, fibrosis) enhance generalizability of findings.
Limitations
- Single-center retrospective scoring with small sample size; risk of selection bias.
- Proposed cutoff lacks external validation; confounding by indication cannot be excluded.
Future Directions: Externally validate PRESERVE-CO2 across centers and devices, integrate with physiologic predictors into decision algorithms, and test prospectively whether score-guided ECCO2R improves outcomes.
Introduction Hypercapnic respiratory failure is associated with high morbidity and mortality. Low-flow extracorporeal CO2 removal (ECCO2R) has been shown to facilitate lung protective ventilation or spontaneous breathing. However, three multicenter randomized trials have failed to show benefit which could potentially be a result of patient selection. In this study, we aimed to characterize prognostic scores developed for extracorporeal membrane oxygenation therapy which could potentially assist with the selection of patients for ECCO2R. Methods 70 patients admitted to the ICU at the University Hospital of Zurich between 10/2009 and 02/2017 with hypercapnic respiratory failure were treated with ECCO2R if pH ≤ 7.25 and/or PaCO2 ≥ 9kPa experiencing respiratory exhaustion during spontaneous breathing in obstructive lung disease or reaching the limits of lung protective ventilation (n=22 and n=48) in patients with restrictive lung pathologies. Data including baseline characteristics and respiratory parameters were collected prospectively. Scores were calculated retrospectively. Results The underlying diseases were ARDS (n=27), COPD (n=12), bronchiolitis obliterans syndrome (n=9), cystic fibrosis (n=10), pulmonary fibrosis (n=8) and other causes (n=4). 180-day mortality was 45.7% with the highest rate observed in PF and BOS patients as well as in patients who had been mechanically ventilated > 6 days before initiation of ECCO2R. The modified PRedicting dEath for SEvere hypercapnic Respiratory failure on vv-ECCO2R (PRESERVE-CO2) score differentiated well between survivors and non-survivors (4.3 ± 2.2 vs 6.9 ± 2.6, p < 0.01), whereas the modified Respiratory ECMO Survival Prediction (RESP-CO2) score showed no significant distinction. Receiver operating characteristics analysis of the PRESERVE-CO2 score revealed an area under the curve of 0.78, suggesting a cut-off of 7 points. Conclusion Careful selection of patients for ECCO2R therapy may help to improve outcomes. The proposed PRESERVE-CO2 score may serve as a guide. A score of 7 points or higher is associated with an unfavorable outcome regarding the 180-day mortality in the specific patient cohort of this study, but future studies to externally validate this score are required.